Explore NIH definitions, policies, and grant opportunities tailored for new and early-stage investigators in cancer research.

Introduction

Embarking on a career in cancer research is both challenging and rewarding. Securing adequate cancer research funding is crucial for new and early-stage investigators (ESIs) to advance their work and contribute to groundbreaking discoveries. The Division of Cancer Control and Population Sciences (DCCPS) offers a range of resources and grants specifically designed to support emerging researchers in this vital field.

Understanding NIH Definitions

Early-Stage Investigator (ESI)

An Early-Stage Investigator (ESI) is defined by the National Institutes of Health (NIH) as a researcher who has completed their terminal research degree or medical residency within the past 10 years and has not yet been awarded a substantial, competing NIH research grant. This designation aims to support those at the beginning of their independent research careers, providing them with opportunities to establish themselves in the competitive landscape of cancer research.

New Investigator

A New Investigator is typically a Program Director/Principal Investigator (PD/PI) who has not previously competed successfully as a PD/PI for a substantial NIH independent research award beyond early-stage or small research grants, training, infrastructure, or career awards. This status ensures that those new to the NIH funding process receive the necessary support to develop their research initiatives without the burden of sustaining preliminary funding.

Funding Opportunities for ESIs and New Investigators

Pathway to Independence Award (K99/R00)

The Pathway to Independence Award (K99/R00) is designed to facilitate the transition of early-stage scientists from mentored postdoctoral positions to stable independent research roles. This award provides up to five years of support divided into two phases:

Phase 1: Offers 1-2 years of mentored support for promising postdoctoral researchers.
Phase 2: Provides up to 3 years of independent support contingent upon securing an independent research position.

During this period, awardees are expected to compete successfully for independent R01 grants, thereby strengthening their ability to sustain long-term research projects in cancer science.

NIH Director’s New Innovator Award (DP2)

The NIH Director’s New Innovator Award (DP2) aims to stimulate highly innovative research and support promising new investigators. Applicants must qualify as ESIs and demonstrate novel approaches that have the potential to transform scientific understanding or clinical practice in cancer research. This award fosters creativity and risk-taking, essential components for pioneering advancements in the field.

Training and Resources

NIH Regional Grants Seminars

Each year, the NIH sponsors two Regional Grants Seminars focused on program funding and grants management. These seminars are invaluable for grants administrators, new NIH researchers, and graduate students. They offer insights into the application and review processes, federal regulations, and current areas of interest, equipping investigators with the knowledge needed to navigate the cancer research funding landscape effectively.

NIH Tips for Applicants

In the “NIH Tips for Applicants” video series, NIH reviewers and staff share strategies to enhance grant applications. These tips cover everything from crafting compelling proposals to avoiding common pitfalls, thereby increasing the chances of securing funding for cancer research projects.

FAQs

I have never applied for NIH funding. What do I need to know to start the process?

Begin by regularly reviewing NIH Notices of Funding Opportunities (NOFOs) in the NIH Guide to Grants and Contracts. Subscribing to updates and contacting BRP Program Directors for guidance can also provide valuable support throughout the application process.

What is the difference between a Pathway to Independence Award (K99/R00), an NIH Director’s New Innovator Award, and other NIH grant mechanisms?

The K99/R00 award focuses on transitioning researchers to independence, while the New Innovator Award (DP2) emphasizes highly innovative research from ESIs. Other grant mechanisms, such as the Pioneer Award or Transformative R01s, have their distinct focuses and eligibility criteria tailored to different aspects of cancer research funding.

Can I still be considered a New Investigator if I led a sub-project on a multi-component grant?

Yes. Only those who have successfully competed as PIs for significant independent NIH research grants are excluded from being considered New Investigators.

How can I tell if NIH considers me an Early-Stage Investigator (ESI)?

If you are within 10 years of completing your terminal research degree or medical residency and have not yet received a substantial NIH research grant, you qualify as an ESI.

For more detailed information, refer to the NIH New and Early-Stage Investigator Guidelines.

Conclusion

Navigating the realm of cancer research funding can be daunting for new and early-stage investigators. However, with the right resources and support from programs like those offered by DCCPS, aspiring researchers can secure the necessary grants to propel their work forward. Understanding NIH definitions, leveraging available training, and accessing targeted funding opportunities are essential steps in building a successful career in cancer research.

Unlock your potential in cancer research funding today. Explore comprehensive support and grant opportunities at Capital Democracy.